| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 2, 2015 | AKBA Akebia Therapeutics, Inc. | Hadas Nicole R.60 | VP General Counsel &Secretary | Sell | 1,715 | $11.46 | $19,655.10 | -2.3% | |
| Jan 2, 2015 | AKBA Akebia Therapeutics, Inc. | Nash Duane | Director | Sell | 995 | $11.46 | $11,403.40 | -7.2% | |
| Sep 22, 2014 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Buy | 325,000 | $15.00 | $4,875,000.00 | +7.5% | |
| Sep 20, 2012 | NVS Novartis AG | Novartis AG | 10% Owner | Sell | 1,551,896 | $19.42 | $30,137,820.32 | -27.7% | |
| Feb 23, 2012 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 84,893 | $3.43 | $291,282.90 | - | |
| Nov 22, 2011 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 50,530 | $4.08 | $206,400.37 | - | |
| Oct 4, 2011 | MRK Merck & Co., Inc. | Weeks Wendell P62 | Director | Sell | 100 | $31.35 | $3,135.00 | -100% | |
| Apr 13, 2011 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 1,785,714 | $2.80 | $4,999,999.20 | +5.7% | |
| Feb 25, 2011 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 20,993 | $2.64 | $55,416.68 | - | |
| Jan 26, 2011 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 167,505 | $1.14 | $191,697.72 | -0.3% | |
| Jan 24, 2011 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 142,300 | $1.23 | $174,439.97 | -0.3% | |
| Jan 20, 2011 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 5,700 | $1.47 | $8,364.00 | - | |
| Jan 20, 2011 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 88,500 | $1.44 | $127,116.49 | -0.1% | |
| Nov 26, 2010 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 17,083 | $2.73 | $46,689.69 | - | |
| Aug 23, 2010 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 37,214 | $2.45 | $91,009.11 | - | |
| Jun 8, 2010 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 1,351 | $2.41 | $3,255.91 | - | |
| Apr 23, 2010 | NVS Novartis AG | Novartis AG | 10% Owner | Buy | 55,223 | $17.99 | $993,461.77 | +1.0% | |
| Feb 26, 2010 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 1,872 | $2.41 | $4,511.52 | - | |
| Aug 21, 2009 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 3,431 | $2.41 | $8,268.71 | - | |
| May 29, 2009 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 2,451 | $2.62 | $6,421.62 | - | |
| May 6, 2009 | NVS Novartis AG | Novartis AG | 10% Owner | Buy | 65,922 | $17.50 | $1,153,635.00 | +1.2% | |
| Feb 23, 2009 | NVS Novartis AG | Novartis AG | Indirect 10% Owner | Buy | 5,444 | $2.41 | $13,120.04 | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.